Dechra has launched Pergocoat, for the treatment of Pituitary Pars Intermedia Dysfunction (PPID), aka equine Cushing’s disease.

Pergocoat contains pergolide, a long-acting dopamine receptor agonist.

It is available in 0.5mg (off-white) and 1mg (yellow) tablets for accurate dosing without the need to split tablets. 

The tablets are film-coated to mask the bitter taste of pergolide and create a barrier between the horse owner and the active ingredient.

Available in two different pack sizes containing 60 or 160 tablets, Pergocoat tablets are packaged in double layered blister packs to help minimise the risk of accidental ingestion.

Rachel Addison BVM&S MRCVS, equine field support manager at Dechra said: “Pergocoat is available in two convenient tablet sizes to achieve an optimal treatment response. 

"Horses can be monitored and reviewed every four to six weeks until stabilisation or improvement of clinical signs is observed.”

https://www.dechra.co.uk/products/horse/prescription/pergocoat#Pergocoat-0-5mg-60-film-coated-tablets-for-horses. 

PS: Whilst you're here, take a moment to see our latest job opportunities for vet nurses.